We are live on ! Find out more
GSK icon

GSK
GSK

763 hedge funds and large institutions have $9.69B invested in GSK in 2017 Q4 according to their latest regulatory filings, with 135 funds opening new positions, 168 increasing their positions, 348 reducing their positions, and 109 closing their positions.

New
Increased
Maintained
Reduced
Closed

24% more first-time investments, than exits

New positions opened: 135 | Existing positions closed: 109

3% more funds holding

Funds holding: 741 → 763 (+22)

7% more call options, than puts

Call options by funds: $107M | Put options by funds: $99.7M

0.46% more ownership

Funds ownership: 3.95% → 4.41% (+0.46%)

2% less capital invested

Capital invested by funds: $9.84B → $9.69B (-$148M)

10% less funds holding in top 10

Funds holding in top 10: 10 → 9 (-1)

52% less repeat investments, than reductions

Existing positions increased: 168 | Existing positions reduced: 348

Holders
763
Holders Change
+22
Holders Change %
+2.97%
% of All Funds
17.31%
Holding in Top 10
9
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-10%
% of All Funds
0.2%
New
135
Increased
168
Reduced
348
Closed
109
Calls
$107M
Puts
$99.7M
Net Calls
+$7.16M
Net Calls Change
-$43.6M

Top Buyers

Rank Fund Capital Flow
1
Dodge & Cox
Dodge & Cox
California
+$1.08B
2
Royal Bank of Canada
Royal Bank of Canada
Ontario, Canada
+$624M
3
Two Sigma Advisers
Two Sigma Advisers
New York
+$66.9M
4
CCM
Camber Capital Management
Massachusetts
+$55.4M
5
Millennium Management
Millennium Management
New York
+$48.7M

Top Sellers

Rank Fund Capital Flow
1
Wells Fargo
Wells Fargo
California
-$197M
2
Bank of America
Bank of America
North Carolina
-$125M
3
HCM
Hamlin Capital Management
New York
-$72M
4
MHI
Miller Howard Investments
New York
-$56.4M
5
Morgan Stanley
Morgan Stanley
New York
-$38.2M
Name Holding Trade Value Shares
Change 		Change in
Stake
JMPWA
176
JP Morgan Private Wealth Advisors
California
$2.67M -$1.33M -28,801 -32%
OC
177
Oppenheimer & Co
New York
$2.65M -$654K -14,151 -19%
EVM
178
Eaton Vance Management
Massachusetts
$2.64M -$7.25K -157 -0.3%
HH
179
Hilltop Holdings
Texas
$2.59M +$189K +4,088 +8%
JGUA
180
John G. Ullman & Associates
New York
$2.56M -$3.98M -86,238 -60%
N
181
Natixis
France
$2.56M +$2.36M +51,096 +778%
FB
182
Fulton Bank
Pennsylvania
$2.55M -$128K -2,765 -5%
FIM
183
Foresters Investment Management
New York
$2.51M +$18.5K +400 +0.7%
TG
184
TCW Group
California
$2.47M -$188K -4,064 -7%
MCM
185
Marathon Capital Management
Maryland
$2.45M -$13K -281 -0.5%
Pacer Advisors
186
Pacer Advisors
Pennsylvania
$2.43M +$943K +20,404 +59%
ZAM
187
Zevin Asset Management
Massachusetts
$2.43M +$490K +10,600 +24%
ACM
188
Azimuth Capital Management
Michigan
$2.43M +$383K +8,288 +18%
GIM
189
Greylin Investment Management
Virginia
$2.41M -$1.6M -34,708 -39%
SPIA
190
Steward Partners Investment Advisory
New York
$2.39M +$2.19M +47,448 +733%
UR
191
USCA RIA
Texas
$2.33M +$1.27M +27,538 +110%
RA
192
Rational Advisors
New York
$2.31M +$1.85M +40,000 +328%
BF
193
BOK Financial
Oklahoma
$2.29M -$1.04M -22,516 -30%
BNP Paribas Financial Markets
194
BNP Paribas Financial Markets
France
$2.27M -$1.41M -30,567 -37%
TNBTD
195
Trustmark National Bank Trust Department
Mississippi
$2.25M +$855K +18,506 +57%
PRS
196
Pinkerton Retirement Specialists
Idaho
$2.25M +$52.5K +1,137 +2%
SWMG
197
Signature Wealth Management Group
Georgia
$2.24M +$2.33M +50,436 New
MWP
198
MYCIO Wealth Partners
Pennsylvania
$2.16M +$48.2K +1,043 +2%
OPPM
199
Opus Point Partners Management
New York
$2.13M – – –
MHC
200
Meyer Handelman Company
New York
$2.12M +$48K +1,040 +2%
6 7
8
9 10

GSK Hedge Fund Activity: Q4 2017 in Review

763 of the 4,409 institutional investors tracked by Wall St. Rank reported a position in GSK (GSK) for Q4 2017, worth a combined $9.69B — down 1.5% from $9.84B a quarter earlier.

Buyers outnumbered sellers: 135 funds opened new GSK positions and 109 closed out — a net gain of 26 holders — while 168 added to existing stakes and 348 trimmed.

The largest buyer was Dodge & Cox, adding an estimated $1.08B. The largest seller was Wells Fargo, cutting an estimated $197M.

  • 763 institutional investors held GSK (GSK) as of Q4 2017, up from 741 in Q3 2017.
  • Funds reported $9.69B of GSK stock for Q4 2017, down 1.5% quarter-over-quarter.
  • 135 funds opened new GSK positions in Q4 2017 and 109 closed out, a net change of +26 holders.
  • The largest GSK buyer in Q4 2017 was Dodge & Cox, an estimated $1.08B added.
  • The largest GSK seller in Q4 2017 was Wells Fargo, an estimated $197M sold.

Based on aggregated 13F filings for Q4 2017.